Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have partnered to build an oligonucleotide cGMP manufacturing facility spanning an area of 59,000 square feet (approx. 5,481 square meters) in Berlin.   This collaboration aims to accelerate the development and commercialization of oligonucleotide-based therapies to improve quality of life for patients worldwide.   Oligonucleotide therapies offer a targeted approach to modulating gene expression, splicing, and protein p...